Emactuzumab (Synonyms: RG 7155; RO 5509554) |
| رقم الكتالوجGC66380 |
Emactuzumab (RG 7155) هو جسم مضاد أحادي النسيلة يثبط تنشيط مستقبل عامل تحفيز القولون 1 (CSF1R). يمتلك Emactuzumab تقاربًا كبيرًا مع CSF-1R بقيمة Ki تبلغ 0.2 نانومتر لحجب إضعاف CSF-1R. يمكن استخدام Emactuzumab للبحث في العديد من الأمراض ، مثل ورم الخلايا العملاقة المنتشر من نوع tenosynovial العملاقة (dt-GCT).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1448221-67-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 0.2 nM (CSF-1R)[2]
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) [1][2].
Emactuzumab (RG 7155) binds to human and cynomolgus CSF-1R with high affinity (Kd = 0.2 nM) to blocks CSF-1R dimerization[2].
RG7155 (0-10 μg/mL, 7 days) potently inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM by inducing cell death[2].
RG7155 (30 μg/mL, 6 days) induces cell death of in vitro-differentiated human M2-like macrophages[2].
Cell Viability Assay[2]
| Cell Line: | CSF-1 and/or GM-CSF Macrophages |
| Concentration: | 0-10 μg/mL |
| Incubation Time: | 7 days |
| Result: | Resulted cell death of CSF-1-differentiated macrophages. |
Emactuzumab(RG 7155) (i.v.; 0.1??1??10??30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates' peripheral blood[2].
RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1R+CD163+ macrophages in vivo[2].
| Animal Model: | cynomolgus monkeys Macaca fascicularis[2] |
| Dosage: | 0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys) 0, 30, and 100 mg/kg (male and female cynomolgus) |
| Administration: | i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks(male and female cynomolgus) |
| Result: | Increased CSF-1 concentration in serum. Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *